Nasdaq: LTGO · Listed Aug 7, 2026
Latigo Biotherapeutics IPO
IPO price
$18.00
Latigo Biotherapeutics (LTGO) priced its IPO at $18.00 a share and has traded on Nasdaq since Aug 7, 2026.
LTGO today$13.31-26.06%since IPO15-min delayed · as of 5:19:44 PM EST on Nov 18, 2026
See the LTGO quoteFirst trading day · Aug 7, 2026
- IPO price
- $18.00
- the top of the range of $16 to $18
- First trade
- $21.00
- +16.67% from the IPO price
- First-day last trade
- $18.25
- +1.39% from the IPO price, regular session
- Raise
- $345.6M
- before the underwriters' option
These numbers are from the first trading day, Aug 7, 2026.
How LTGO did against the market
LTGO against the market, from its first trade at 11:40 ET to the last trade of the session.
- LTGO from its first trade
- -13.10%
- Against the market (QQQ)
- -13.1 pts
LTGO fell 13.1% from its first trade to the last trade of the session. That is 13.1 points worse than the market.
Same-day moves do not show that LTGO caused them. The market is QQQ, the Nasdaq-100 ETF.
The debut race
LTGO against other big listings, as the percent change from each stock's own IPO price.
The first 30 trading days. Each point is the last regular-session trade of a day.
The first trading day.
The first trading day.
The IPO scoreboard
LTGO against 6 other big listings: the return from each IPO's own price at the first trade, the close of day 1, day 5, and day 30.
| IPO | Raised | First trade | Day 1 close | Day 1 close, as a bar | Day 5 | Day 30 |
|---|---|---|---|---|---|---|
| Latigo Biotherapeutics '26 | $345.6M | +16.67% | +1.39% | +11.17% | +24.39% | |
| Figma '25 | $1.22B | +157.58% | +252.42% | +173.64% | +69.64% | |
| Circle '25 | $1.05B | +122.58% | +168.45% | +278.18% | +622.98% | |
| Reddit '24 | $748M | +38.24% | +47.97% | +69.90% | +40.32% | |
| Arm '23 | $5.23B | +10.00% | +23.76% | +3.63% | -3.06% | |
| Klarna '25 | $1.37B | +30.00% | +16.14% | +13.73% | -7.33% | |
| CoreWeave '25 | $1.5B | -2.50% | +0.02% | +34.32% | +28.42% |
Day 1 is the last regular-session trade of the first day. Day 5 and day 30 are the last trade of the fifth and thirtieth trading day, counting the listing day as day 1. A cell fills in when that day has traded.
The offering
The Latigo Biotherapeutics IPO offers 19.2M shares to raise $345.6M, before any underwriters' option.
- Expected price range
- $16 to $18
- IPO price
- $18.00
- Shares offered
- 19.2M
- Money raised
- $345.6M
- Listing date
- Aug 7, 2026
- Exchange
- Nasdaq
- Security
- Ordinary Shares
Money raised, against the largest IPOs
- Alibaba '14$21.77B
- Facebook '12$18.41B
- Rivian '21$11.93B
- Uber '19$8.1B
- Arm '23$5.23B
- Latigo Biotherapeutics$345.6M
Where LTGO ranks
Latigo Biotherapeutics's market cap against the largest US-listed companies.
Market cap, against the largest US-listed companies
- AAPL$5.12T
- MSFT$3.77T
- NVDA$3.65T
- GOOGL$3.47T
- AMZN$2.9T
- TSM$1.88T
- AVGO$1.69T
- META$1.58T
- TSLA$1.52T
- BRK.B$1.22T
- LTGO$882.44M
Filings and the company
What Latigo Biotherapeutics has disclosed to the SEC, and the basic facts about the listing.
8-K filings
Material events that Latigo Biotherapeutics discloses to the SEC on Form 8-K.
- Quarterly earningsNov 5, 2026
On November 5, 2026, Latigo Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended September 30, 2026.
- Quarterly earningsSep 3, 2026
On September 3, 2026, Latigo Biotherapeutics, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2026.
- Public offeringAug 10, 2026
On August 10, 2026, the Company completed its IPO of an aggregate of 19,200,000 shares of common stock at a price to the public of $18.00 per share. The aggregate gross proceeds from the IPO, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company, were approximately $345.6 million.
About Latigo Biotherapeutics
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.
- Ticker
- LTGO
- Exchange
- Nasdaq
- Market
- stocks
- Type
- CS
- Currency
- USD
- Industry
- PHARMACEUTICAL PREPARATIONS
- Listed
- Aug 7, 2026
- Security
- Ordinary Shares
Frequently asked questions
What was the Latigo Biotherapeutics IPO price?
$18.00 a share.
When did Latigo Biotherapeutics go public?
Latigo Biotherapeutics listed on Nasdaq on Aug 7, 2026 under the ticker LTGO.
How much did the Latigo Biotherapeutics IPO raise?
$345.6M, before any underwriters' option.
How did Latigo Biotherapeutics open on its first day?
LTGO first traded at $21.00, +16.67% from the IPO price of $18.00.
How did LTGO close on its first day?
Its last regular-session trade was $18.25, +1.39% from the IPO price of $18.00.
What was the LTGO first-day trading range?
$18.19 to $22.47 in the regular session.
How many LTGO shares traded on the first day?
3.23M shares in the regular session.
How many shares did Latigo Biotherapeutics sell in its IPO?
19.2M shares.
How did LTGO do against the market on its first day?
LTGO fell 13.1% from its first trade to the last trade of the session. That is 13.1 points worse than the market (QQQ, the Nasdaq-100 ETF).
What exchange is LTGO listed on?
Latigo Biotherapeutics lists on Nasdaq under the ticker LTGO.
Build with Massive
Get the LTGO data behind this page
| What the page shows | Endpoint |
|---|---|
| Offering terms and dates | /vX/reference/ipos |
| Price | /v3/snapshot |
| Chart, VWAP, and the market comparison | /v2/aggs/ticker/LTGO/range/5/minute |
| Market cap | /v3/reference/tickers/LTGO |
| News | /v2/reference/news |
| Filings | /vX/disclosures |
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.